Immutep Limited (ASX: IMM; NASDAQ: IMMP) received a Nasdaq bid‑price deficiency notice on April 30, 2026, after its American Depositary Shares fell below the $1.00 minimum bid price for 30 consecutive business days ending April 24, 2026.
The notice is issued under Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00. Immutep was granted a 180‑day compliance period that expires on October 26, 2026; during that time the company must achieve a closing bid price of at least $1.00 for ten consecutive business days to regain compliance.
The decline in bid price coincides with the discontinuation of Immutep’s TACTI‑004 Phase III trial in March 2026, a key development program that likely contributed to investor sentiment and the drop in ADS price. Despite the bid‑price issue, the company holds substantial cash reserves—approximately A$99.1 million in cash and cash equivalents as of December 31, 2025, rising to A$129.3 million in January 2026 after a payment from Dr. Reddy’s—providing a buffer against liquidity concerns.
The deficiency notice signals a listing risk that could lead to delisting if compliance is not achieved. It also highlights potential liquidity concerns and may affect market perception of Immutep’s financial health. The company has indicated it will monitor the bid price and consider available options, but recent Nasdaq rule changes limit the feasibility of reverse stock splits as a cure, adding complexity to its compliance strategy.
Immutep’s management must decide whether to pursue a reverse split, adjust capital structure, or implement other measures to lift the bid price above $1.00. The company’s strong cash position provides a cushion, but the bid‑price deficiency remains a significant regulatory hurdle that investors will closely monitor.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.